Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Capital Expenditures (2021 - 2024)

Historic Capital Expenditures for InMed Pharmaceuticals (INM) over the last 4 years, with Q1 2024 value amounting to $2.0.

  • InMed Pharmaceuticals' Capital Expenditures changed N/A to $2.0 in Q1 2024 from the same period last year, while for Jun 2024 it was $31818.0, marking a year-over-year increase of 11776.79%. This contributed to the annual value of $9293.0 for FY2024, which is 9419.24% down from last year.
  • InMed Pharmaceuticals' Capital Expenditures amounted to $2.0 in Q1 2024.
  • InMed Pharmaceuticals' 5-year Capital Expenditures high stood at $250000.0 for Q3 2021, and its period low was -$214445.0 during Q4 2021.
  • Over the past 4 years, InMed Pharmaceuticals' median Capital Expenditures value was $3553.0 (recorded in 2022), while the average stood at $14185.2.